These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36305182)

  • 1. Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
    van Zyl G; Jennings L; Kellermann T; Nkantsu Z; Cogill D; van Schalkwyk M; Spinelli M; Decloedt E; Orrell C; Gandhi M
    AIDS; 2022 Nov; 36(14):2057-2062. PubMed ID: 36305182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
    Jennings L; Kellermann T; Spinelli M; Nkantsu Z; Cogill D; van Schalkwyk M; Decloedt E; van Zyl G; Orrell C; Gandhi M
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):455-462. PubMed ID: 34779228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
    Dorward J; Lessells R; Govender K; Moodley P; Samsunder N; Sookrajh Y; Turner P; Butler CC; Hayward G; Gandhi M; Drain PK; Garrett N
    J Int AIDS Soc; 2023 Sep; 26(9):e26172. PubMed ID: 37735860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure.
    McCluskey SM; Govender K; Adamson J; Gandhi M; Spinelli MA; Moosa MY; Muyindike W; Moodley P; Pillay M; Masette G; Sunpath H; Pillay S; Chen G; Hedt-Gauthier B; Marconi VC; Siedner MJ
    AIDS; 2023 Jun; 37(7):1109-1113. PubMed ID: 36928169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
    Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing a point-of-care urine tenofovir lateral flow assay to self-reported adherence and their associations with viral load suppression among adults on antiretroviral therapy.
    Phillips T; Gomba Y; Myer L
    Trop Med Int Health; 2024 Feb; 29(2):96-103. PubMed ID: 38084797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
    Morrow M; MaWhinney S; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Anderson PL; Castillo-Mancilla JR
    J Infect Dis; 2019 Jul; 220(4):635-642. PubMed ID: 30942881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.
    Jennings L; Robbins RN; Nguyen N; Ferraris C; Leu CS; Dolezal C; Hsiao NY; Mgbako O; Joska J; Castillo-Mancilla JR; Myer L; Anderson PL; Remien RH; Orrell C;
    AIDS; 2022 Jun; 36(7):933-940. PubMed ID: 35131960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
    Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
    Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
    Singh Y; Castillo-Mancilla J; Madimabe R; Jennings L; Ferraris CM; Robbins RN; Anderson PL; Remien RH; Orrell C
    AIDS Res Ther; 2023 Sep; 20(1):67. PubMed ID: 37705102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
    Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
    Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
    Grinsztejn B; Hughes MD; Ritz J; Salata R; Mugyenyi P; Hogg E; Wieclaw L; Gross R; Godfrey C; Cardoso SW; Bukuru A; Makanga M; Faesen S; Mave V; Wangari Ndege B; Nerette Fontain S; Samaneka W; Secours R; van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Avihingsanon A; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC;
    Lancet HIV; 2019 Sep; 6(9):e588-e600. PubMed ID: 31371262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Tenofovir Diphosphate Levels to Predict Viremia During the Postpartum Period in Women Living With Human Immunodeficiency Virus (HIV): A Nested Case-Control Study.
    Odayar J; Orrell C; Phillips TK; Hu NC; Kabanda S; Malaba TR; Allerton J; Wiesner L; Hsiao NY; Castillo-Mancilla J; Lesosky M; Myer L
    Clin Infect Dis; 2022 Sep; 75(5):761-767. PubMed ID: 34979553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Point-of-Care Tenofovir Urine Testing for the Prediction of Treatment Failure and Drug Resistance During Initial Treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection.
    Hermans LE; Umunnakwe CN; Lalla-Edward ST; Hebel SK; Tempelman HA; Nijhuis M; Venter WDF; Wensing AMJ
    Clin Infect Dis; 2023 Feb; 76(3):e553-e560. PubMed ID: 36136811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV.
    Sribenjalux W; Nuntawit T; Meesing A; Chetchotisakd P
    Int J STD AIDS; 2023 Feb; 34(2):98-107. PubMed ID: 36378013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
    Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
    Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining the acceptability of point-of-care urine tenofovir testing and its performance in predicting HIV RNA suppression.
    Marryshow TA; Muhairwe J; Tang A; Molulela MMM; Matta R; Jordan MR
    Int J STD AIDS; 2022 Jul; 33(8):777-783. PubMed ID: 35611960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
    Yager JL; Coyle RP; Coleman SS; Ellison L; Zheng JH; Bushman L; Gardner EM; Morrow M; MaWhinney S; Anderson PL; Justice Kiser J; Castillo-Mancilla JR
    J Int Assoc Provid AIDS Care; 2019; 18():2325958219888457. PubMed ID: 31750768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.